Rhythm Pharmaceuticals gains on Q1 revenue growth

Rhythm Pharmaceuticals

05/05/2026 14:11

** Shares of Rhythm Pharmaceuticals RYTM.O rise 8.7% to $93 premarket

** Drugmaker reports Q1 product revenue of $60.1 mln vs $32.7 mln a year ago

** Revenue growth was primarily driven by the launch of IMCIVREE for acquired hypothalamic obesity, per co

** Co posts Q1 net loss of $55.6 mln, nearly in line with  analyst consensus of a loss of $55.3 mln, according to LSEG data

** 15 of 16 brokerages rate the stock "buy" or higher, one "hold"; their median PT is $140- LSEG data

** Up to last close stock down 20%, YTD

 (Reporting by Avinash P in Bengaluru)

 ((Avinash.P@thomsonreuters.com;))